{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:06:22Z","timestamp":1784538382611,"version":"3.55.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nonvertebral fractures (NVFs) in patients with Duchenne muscular dystrophy (DMD) are often associated with an unfavorable prognosis. However, the influencing factors and early warning indicators for NVFs remain unclear. To address this knowledge gap, a retrospective cohort study was conducted across 2 centers involving 295 DMD patients who were evaluated between August 2013 and February 2022. Data collection included telephone callback records and outpatient face-to-face assessments. Among the 295 patients, 30 (10.2%) had experienced at least 1 NVF. The overall NVF incidence rate was 91.8 (95% CI, 62.4-130.3) per 10\u2009000 person-years, representing a rate more than 5 times higher than that of traumatic NVFs in boys aged 0-14\u00a0yr. This finding underscores the significant burden of NVFs in DMD patients. Subsequent analysis investigated the association between the occurrence of the first NVF and various factors, including ambulant status, glucocorticoid (GC) regimen, and dystrophin isoform expression. Multivariate analysis revealed that ambulation was a significant risk factor for the first NVF, with an increased risk of 29.2-fold (95% CI, 3.9-217.3, p\u2009&amp;lt;\u00a0.001). In contrast, a longer GC-na\u00efve duration exhibited a protective effect against the first NVF, reducing the risk to 0.804-fold per year (95% CI, 0.691-0.936, p\u2009=\u00a0.005). In patients aged 8-13\u00a0yr, motor function parameters 1 yr before the first NVF, including the 6-min walking distance (6MWD), the 10-m walking test time (10mWT), and the time from supine to standing (TSS), were significantly worse compared with those without NVF. Specifically, the 6MWD was shorter (p\u2009=\u2009.007), while 10mWT and TSS were longer (p\u2009=\u2009.025 and p\u2009=\u2009.020, respectively). Receiver operating characteristic curves indicated that a 6MWD of 248.2\u00a0m and a 10mWT of 9.85\u00a0s were the optimal cut-off values for predicting the onset of the first NVF, suggesting that a decline in the 6MWD to ~250\u00a0m and an increase in the 10mWT to ~10\u00a0s may serve as early warning indicators.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag098","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:46:19Z","timestamp":1781091979000},"source":"Crossref","is-referenced-by-count":0,"title":["Influencing factors and early warning indicators for nonvertebral fractures in patients with Duchenne muscular dystrophy"],"prefix":"10.1093","volume":"10","author":[{"given":"Changping","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"School of Medicine, Nankai University , Tianjin 300071 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Third Medical Center of Chinese PLA General Hospital , Beijing 100039 ,","place":["China"]},{"name":"Anhui Medical University , Hefei 230032, Anhui ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Center for Translational Genomics and Rare Diseases, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Beijing Key Laboratory of Gene Editing Therapy for Hereditary Neuromuscular Diseases , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-5293","authenticated-orcid":false,"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Center for Translational Genomics and Rare Diseases, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Beijing Key Laboratory of Gene Editing Therapy for Hereditary Neuromuscular Diseases , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandai","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"School of Medicine, Nankai University , Tianjin 300071 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Center for Translational Genomics and Rare Diseases, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Beijing Key Laboratory of Gene Editing Therapy for Hereditary Neuromuscular Diseases , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-088X","authenticated-orcid":false,"given":"Shengyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"School of Medicine, Nankai University , Tianjin 300071 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1023-4073","authenticated-orcid":false,"given":"Shiwen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Center for Translational Genomics and Rare Diseases, The First Medical Center of Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]},{"name":"Beijing Key Laboratory of Gene Editing Therapy for Hereditary Neuromuscular Diseases , Beijing 100853 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"Pt 1","key":"2026072004363871900_ref1","doi-asserted-by":"publisher","first-page":"130544","DOI":"10.1016\/j.ijbiomac.2024.130544","article-title":"A review on mechanistic insights into structure and function of dystrophin protein in pathophysiology and therapeutic targeting of Duchenne muscular dystrophy","volume":"264","author":"Elasbali","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"2026072004363871900_ref2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"2026072004363871900_ref3","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.3390\/ijms21134596","article-title":"Anti-inflammatory and general glucocorticoid physiology in skeletal muscles affected by Duchenne muscular dystrophy: exploration of steroid-sparing agents","volume":"21","author":"Herbelet","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026072004363871900_ref4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11914-018-0468-2","article-title":"Targeting the muscle-bone unit: filling two needs with one deed in the treatment of Duchenne muscular dystrophy","volume":"16","author":"Boulanger Piette","year":"2018","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2026072004363871900_ref5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR correction of Duchenne muscular dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Annu Rev Med"},{"issue":"6","key":"2026072004363871900_ref6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/mus.27514","article-title":"Assessment of the relationship between disease progression and goals of care by individuals with Duchenne muscular dystrophy and their caregivers","volume":"65","author":"Grossoehme","year":"2022","journal-title":"Muscle Nerve"},{"issue":"10","key":"2026072004363871900_ref7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"2026072004363871900_ref8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11914-017-0396-6","article-title":"Muscle-bone interactions in pediatric bone diseases","volume":"15","author":"Veilleux","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"2026072004363871900_ref9","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1007\/s12325-022-02179-1","article-title":"Effectiveness of neridronate in the management of bone loss in patients with Duchenne muscular dystrophy: results from a pilot study","volume":"39","author":"Moretti","year":"2022","journal-title":"Adv Ther"},{"issue":"8","key":"2026072004363871900_ref10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.nmd.2011.04.008","article-title":"Report on the second endocrine aspects of Duchenne Muscular Dystrophy Conference December 1\u20132, 2010, Baltimore, Maryland, USA","volume":"21","author":"Leung","year":"2011","journal-title":"Neuromuscul Disord"},{"issue":"11\u201312","key":"2026072004363871900_ref11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.nmd.2007.05.008","article-title":"Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy","volume":"17","author":"S\u00f6derpalm","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"2026072004363871900_ref12","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00198-020-05549-z","article-title":"Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy","volume":"31","author":"Nasomyont","year":"2020","journal-title":"Osteoporos Int"},{"key":"2026072004363871900_ref13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pediatrneurol.2016.05.013","article-title":"Recurrent fat embolic strokes in a patient with Duchenne muscular dystrophy with long bone fractures and a patent foramen ovale","volume":"63","author":"Bugnitz","year":"2016","journal-title":"Pediatr Neurol"},{"issue":"11","key":"2026072004363871900_ref14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.nmd.2016.08.011","article-title":"Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy","volume":"26","author":"Tian","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2026072004363871900_ref15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00198-016-3774-5","article-title":"The time to and determinants of first fractures in boys with Duchenne muscular dystrophy","volume":"28","author":"Ma","year":"2017","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026072004363871900_ref16","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.nmd.2012.06.354","article-title":"Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy","volume":"22","author":"Mayo","year":"2012","journal-title":"Neuromuscul Disord"},{"issue":"19","key":"2026072004363871900_ref17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology."},{"issue":"2","key":"2026072004363871900_ref18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"issue":"3\u20134","key":"2026072004363871900_ref19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000095920","article-title":"Copy number variation in the genome; the human DMD gene as an example","volume":"115","author":"White","year":"2006","journal-title":"Cytogenet Genome Res"},{"issue":"8","key":"2026072004363871900_ref20","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2214-109X(17)30222-X","article-title":"National incidence of traumatic fractures in China: a retrospective survey of 512\u2008187 individuals","volume":"5","author":"Chen","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"6","key":"2026072004363871900_ref21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","article-title":"Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK Northstar database","volume":"76","author":"Joseph","year":"2019","journal-title":"JAMA Neurol"},{"issue":"10","key":"2026072004363871900_ref22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1017\/S0012162201002778","article-title":"Fracture prevalence in Duchenne muscular dystrophy","volume":"44","author":"McDonald","year":"2002","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"2026072004363871900_ref23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mus.27762","article-title":"Fracture risk and impact in boys with Duchenne muscular dystrophy: a retrospective cohort study","volume":"67","author":"Liaw","year":"2023","journal-title":"Muscle Nerve"},{"issue":"4","key":"2026072004363871900_ref24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"7","key":"2026072004363871900_ref25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nmd.2020.06.005","article-title":"Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy","volume":"30","author":"Tian","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2026072004363871900_ref26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J Pediatr Orthop"},{"issue":"1","key":"2026072004363871900_ref27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejpn.2017.08.001","article-title":"Basics of bone metabolism and osteoporosis in common pediatric neuromuscular disabilities","volume":"22","author":"Ya\u015far","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"2026072004363871900_ref28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11940-014-0287-4","article-title":"Current treatment and management of dystrophinopathies","volume":"16","author":"Goemans","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"2026072004363871900_ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/928385","article-title":"Optimizing bone health in Duchenne muscular dystrophy","volume":"2015","author":"Buckner","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2026072004363871900_ref30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mus.24163","article-title":"Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"50","author":"Spurney","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1","key":"2026072004363871900_ref31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.nmd.2017.05.012","article-title":"Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop: Morbidity Due to Osteoporosis in DMD: The Path Forward May 12\u201313, 2016, Bethesda, Maryland, USA","volume":"28","author":"Ward","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2026072004363871900_ref32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.26413","article-title":"Use of bone age for evaluating bone density in patients with Duchenne muscular dystrophy: a preliminary report","volume":"59","author":"Al-Zougbi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"1","key":"2026072004363871900_ref33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/MED.0000000000000456","article-title":"Growth, pubertal development, and skeletal health in boys with Duchenne muscular dystrophy","volume":"26","author":"Ward","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"2026072004363871900_ref34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.nut.2015.09.004","article-title":"Impact of corticotherapy, nutrition, and sleep disorder on quality of life of patients with Duchenne muscular dystrophy","volume":"32","author":"Jeronimo","year":"2016","journal-title":"Nutrition."},{"issue":"06","key":"2026072004363871900_ref35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/s-0038-1666846","article-title":"Secondary bone defect in neuromuscular diseases in childhood: a longitudinal \u201cmuscle-bone unit\u201d analysis","volume":"49","author":"Ribstein","year":"2018","journal-title":"Neuropediatrics."},{"issue":"16","key":"2026072004363871900_ref36","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/nu14163304","article-title":"The relationship between obesity and clinical outcomes in young people with Duchenne muscular dystrophy","volume":"14","author":"Billich","year":"2022","journal-title":"Nutrients."},{"issue":"3","key":"2026072004363871900_ref37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"15","key":"2026072004363871900_ref38","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA."},{"issue":"12","key":"2026072004363871900_ref39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology."},{"issue":"20","key":"2026072004363871900_ref40","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology."},{"issue":"9","key":"2026072004363871900_ref41","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9&lt;1344::aid-mus4&gt;3.0.co;2-f","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"issue":"3","key":"2026072004363871900_ref42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s002239900417","article-title":"A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort","volume":"62","author":"LoCascio","year":"1998","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2026072004363871900_ref43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","article-title":"Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up","volume":"38","author":"Houde","year":"2008","journal-title":"Pediatr Neurol"},{"issue":"9","key":"2026072004363871900_ref44","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/jbmr.5650070912","article-title":"Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells","volume":"7","author":"Canalis","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026072004363871900_ref45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/PHM.0000000000001423","article-title":"Retrospective analysis of fractures and factors causing ambulation loss after lower limb fractures in Duchenne muscular dystrophy","volume":"99","author":"Yildiz","year":"2020","journal-title":"Am J Phys Med Rehabil"},{"issue":"9","key":"2026072004363871900_ref46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrendo.2015.89","article-title":"Skeletal changes through the lifespan\u2014from growth to senescence","volume":"11","author":"Farr","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2026072004363871900_ref47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40618-021-01676-4","article-title":"Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates","volume":"45","author":"Catalano","year":"2022","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"2026072004363871900_ref48","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00198-013-2442-2","article-title":"Risk of fracture in patients with muscular dystrophies","volume":"25","author":"Pouwels","year":"2014","journal-title":"Osteoporos Int"},{"key":"2026072004363871900_ref49","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fendo.2019.00794","article-title":"Neuromuscular diseases and bone","volume":"10","author":"Iolascon","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026072004363871900_ref50","doi-asserted-by":"publisher","first-page":"107719","DOI":"10.1016\/j.pharmthera.2020.107719","article-title":"Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"220","author":"Iftikhar","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"8","key":"2026072004363871900_ref51","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.nmd.2017.05.019","article-title":"Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy","volume":"27","author":"Kim","year":"2017","journal-title":"Neuromuscul Disord"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag098\/68513145\/ziag098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/8\/ziag098\/68513145\/ziag098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/8\/ziag098\/68513145\/ziag098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:36:42Z","timestamp":1784536602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag098\/8706338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag098","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,11]]},"article-number":"ziag098"}}